Tigecycline: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
== Background == |
|||
*Glycylcycline antibiotic |
*Glycylcycline antibiotic |
||
== |
===Spectrum of Activity=== |
||
*Related to [[tetracycline]] and [[doxycycline]], with expanded coverage to include [[streptococci]] and [[Enterobacteriaceae]], but without coverage for unusual [[Gram-negative bacteria]] or [[Chlamydia trachomatis]] |
*Related to [[tetracycline]] and [[doxycycline]], with expanded coverage to include [[streptococci]] and [[Enterobacteriaceae]], but without coverage for unusual [[Gram-negative bacteria]] or [[Chlamydia trachomatis]] |
||
*Does cover [[Acinetobacter]] and [[Stenotrophomonas]] |
*Does cover [[Acinetobacter]] and [[Stenotrophomonas]] |
||
=== Pharmacokinetics and Pharmacodynamics === |
|||
* Rapidly concentrates in tissue, but poor concentration in urine and lung tissue |
|||
== Dosing == |
|||
* High dosing may be useful in HAP/VAP with 100 mg IV q12h |
|||
== Safety == |
|||
* Black box warning for increased all-cause mortality (4 vs 3%), likely driven by standard dosing tigecycline in VAP |
|||
[[Category:Glycylcyclines]] |
[[Category:Glycylcyclines]] |
||
Revision as of 13:29, 3 February 2021
Background
- Glycylcycline antibiotic
Spectrum of Activity
- Related to tetracycline and doxycycline, with expanded coverage to include streptococci and Enterobacteriaceae, but without coverage for unusual Gram-negative bacteria or Chlamydia trachomatis
- Does cover Acinetobacter and Stenotrophomonas
Pharmacokinetics and Pharmacodynamics
- Rapidly concentrates in tissue, but poor concentration in urine and lung tissue
Dosing
- High dosing may be useful in HAP/VAP with 100 mg IV q12h
Safety
- Black box warning for increased all-cause mortality (4 vs 3%), likely driven by standard dosing tigecycline in VAP
